Abstract:Introduction: Human tumors, including gastric cancer, frequently express high levels of epidermal growth factor receptors (EGFRs), which are associated with a poor prognosis. Targeted delivery of anticancer drugs to cancerous tissues shows potential in sparing unaffected tissues. However, it has been a major challenge for drug penetration in solid tumor tissues due to the complicated tumor microenvironment. Chemotherapy employing paclitaxel (PTX) is widely used for treating various kinds of cancer including gastric cancer.Methods: Recombinant protein anti-EGFR-iRGD consisting of an anti-EGFR VHH (the variable domain from the heavy chain of the antibody) fused to iRGD, a tumor-specific binding peptide with high permeability were expressed in E. coli BL21 (DE3) and purified by nickel-nitrilotriacetic acid affinity chromatography. We use tumor cell lines (2D), multicellular spheroids (3D), and mice to analyze the antitumor activity of recombinant protein. To investigate the ability of anti-EGFR-iRGD to improve other drugs (e.g. PTX) penetrating into tumor, we used multicellular spheroids and mice.Results: We have successfully constructed a recombinant protein named anti-EGFR-iRGD, a dual target of EGFR and integrin and high permeable protein. It could spread extensively throughout both the multicellular spheroids and the tumor mass. The recombinant protein anti-EGFR-iRGD also exhibited antitumor activity in tumor cell lines (2D), multicellular spheroids (3D), and mice. Moreover, we demonstrated the therapeutic efficacy of PTX combined with anti-EGFR-iRGD on monolayer cells (2D), multicellular spheroids (3D) and tumor-bearing mice for the first time.Conclusion: Our results provide impetus for further studies for potentially using iRGD based fusion protein anti-EGFR-iRGD with standard cytotoxic treatment regimens for enhancing therapy of gastric cancer patients.Figure: P-014 Introduction: Human tumors, including gastric cancer, frequently express high levels of epidermal growth factor receptors (EGFRs), which are associated with a poor prognosis. Targeted delivery of anticancer drugs to cancerous tissues shows potential in sparing unaffected tissues. However, it has been a major challenge for drug penetration in solid tumor tissues due to the complicated tumor microenvironment. Chemotherapy employing paclitaxel (PTX) is widely used for treating various kinds of cancer including gastric cancer. Methods: Recombinant protein anti-EGFR-iRGD consisting of an anti-EGFR VHH (the variable domain from the heavy chain of the antibody) fused to iRGD, a tumor-specific binding peptide with high permeability were expressed in E. coli BL21 (DE3) and purified by nickel-nitrilotriacetic acid affinity chromatography. We use tumor cell lines (2D), multicellular spheroids (3D), and mice to analyze the antitumor activity of recombinant protein. To investigate the ability of anti-EGFR-iRGD to improve other drugs (e.g. PTX) penetrating into tumor, we used multicellular spheroids and mice. Results: We have successfully constructed a recombinant protein named anti-EGFR-iRGD, a dual target of EGFR and integrin and high permeable protein. It could spread extensively throughout both the multicellular spheroids and the tumor mass. The recombinant protein anti-EGFR-iRGD also exhibited antitumor activity in tumor cell lines (2D), multicellular spheroids (3D), and mice. Moreover, we demonstrated the therapeutic efficacy of PTX combined with anti-EGFR-iRGD on monolayer cells (2D), multicellular spheroids (3D) and tumor-bearing mice for the first time. Conclusion: Our results provide impetus for further studies for potentially using iRGD based fusion protein anti-EGFR-iRGD with standard cytotoxic treatment regimens for enhancing therapy of gastric cancer patients. Figure: P-014

P066 Transmission Ofneisseria Gonorrhoeaeamong Men Who Have Sex with Men: an Anatomical Site-Specific Mathematical Model and Impact of Mouthwash

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Synthesis and Anti‐Proliferation Activity Evaluation of Novel 2‐chloroquinazoline As Potential EGFR‐TK Inhibitors

Abstract C182: Phosphodiesterase 10: A novel cancer target.

Synthesis and Biological Evaluation of Anthraquinone Derivatives As Allosteric Phosphoglycerate Mutase 1 Inhibitors for Cancer Treatment.

Co-delivery of P53 and MDM2 Inhibitor RG7388 Using a Hydroxyl Terminal PAMAM Dendrimer Derivative for Synergistic Cancer Therapy.

Developing a Novel P-glycoprotein Inhibitor and Pairing It with Oral Paclitaxel Liposomes for Enhanced Cancer Therapy

Procedurally Targeted Delivery of Antitumor Drugs Using FAPα-Responsive TPGS Dimer-Based Flower-like Polymeric Micelles.

Polyamine-Targeting Gefitinib Prodrug and Its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy

Preclinical Evaluation of 111In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models

Abstract PO-108: Evaluation of Antitumor Activity of Modified-Gemcitabine Solid-Lipid Nanoparticle in Pancreatic Pdx Models

The Bisbenzylisoquinoline Alkaloids, Tetrandine and Fangchinoline, Enhance the Cytotoxicity of Multidrug Resistance-Related Drugs Via Modulation of P-glycoprotein.

Structure-activity relationship study of permethyl ningalin B analogues as P-glycoprotein chemosensitizers

Impact of PEGylation on biodistribution and tumor accumulation of Lipid-Mu peptide-DNA

Optimization of Permethyl Ningalin B Analogs As P-glycoprotein Inhibitors.

Retraction Note: the PI3K/mTOR Dual Inhibitor BEZ235 Nanoparticles Improve Radiosensitization of Hepatoma Cells Through Apoptosis and Regulation DNA Repair Pathway

Structure-based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Metabolic Reactivity Studies of Quinazoline Derivatives for Their Anti-EGFR Activity Against Tumor Angiogenesis

Abstract 6019: Biodistribution, molecular imaging and efficacy evaluation of a novel GPC3-targeted radiopharmaceutical therapy for hepatocellular carcinoma

Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma

P-014A Tumor-penetrating Recombinant Protein Anti-Egfr-irgd Enhance Efficacy of Paclitaxel in 3D Multicellular Spheroids and Gastric Cancer in Vivo

Design, Synthesis and Pharmacological Evaluation of N4,N6-disubstituted Pyrimidine-4,6-diamine Derivatives As Potent EGFR Inhibitors in Non-Small Cell Lung Cancer